Treatment Outcomes of Infectious and Non-infectious Acute Exacerbation of Myositis-Related Interstitial Lung Disease

IntroductionAlthough respiratory infections are common causes of acute respiratory failure (ARF) in patients with myositis-interstitial lung disease (ILD), limited data are available regarding the treatment outcomes by the etiologies of acute exacerbation (AE) of myositis-related ILD (infectious vs. non-infectious). Our study aimed to investigate the treatment outcomes of AE in patients with myositis-related ILD focused on the infectious etiology. MethodsA single center-based retrospective cohort was performed at Hanyang University Hospital between January 2000 and December 2018. A total of 36 patients with AE of myositis-related ILD were consecutively included. The exposure was the etiologies of AE in myositis-related ILD, and the outcome was in-hospital mortality. The infectious etiology was defined as confirmation of bacteria, virus, or fungus in samples obtained from the respiratory tract. ResultsAmong the 36 patients, 17 were diagnosed with infectious AE. The overall in-hospital mortality rate of AE was 47.2%. Although the mortality rate in patients with infectious AE was lower (41.2%) than in those with non-infectious AE (52.6%), this difference was not statistically significant (p = 0.724). A survival analysis showed no significant difference in mortality between patients with infectious AE versus those with non-infectious AE [risk ratio = 0.78, 95% CI = 0.38-1.59]. ConclusionOur study showed that infectious AE is an important cause of mortality in patients with myositis-related ILD, showing a similar risk of mortality as non-infectious AE.

Automated summary

This study aimed to investigate the treatment outcomes of infectious etiology in acute exacerbation (AE) of myositis-related interstitial lung disease (ILD). The findings revealed that infectious AE is an important cause of mortality in these patients, showing a similar risk of mortality as non-infectious AE.